Literature DB >> 22997168

Probabilistic radiographic atlas of glioblastoma phenotypes.

B M Ellingson1, A Lai, R J Harris, J M Selfridge, W H Yong, K Das, W B Pope, P L Nghiemphu, H V Vinters, L M Liau, P S Mischel, T F Cloughesy.   

Abstract

BACKGROUND AND
PURPOSE: Tumor location is a significant prognostic factor in glioblastoma, which may reflect the genetic profile of tumor precursor cells. The purpose of the current study was to construct and analyze probabilistic radiographic atlases reflecting preoperative tumor locations and corresponding demographic, "-omic," and interventional phenotypes to provide insight into potential niche locations of glioblastoma cells of origin.
MATERIALS AND METHODS: Preoperative anatomic MR images in 507 patients with de novo glioblastoma were analyzed. Images were registered to stereotactic space, tumors were segmented, and the stereospecific frequency of tumor occurrence was analyzed statistically by age, extent of resection, MGMT methylation, IDH1 mutation, gene expression subclassification, PTEN loss, PTEN deficiency, EGFR amplification, EGFR variant 3 expression, progression-free survival from the start of radiochemotherapy, and overall survival from initial diagnosis.
RESULTS: Most glioblastomas grow into the periventricular white matter regions adjacent to the subventricular zone. MGMT promoter methylated tumors occur more frequently in the left temporal lobe, in young patients with glioblastoma, in IDH1 mutant tumors, in tumors having the proneural gene expression subtype, and in tumors lacking loss of PTEN occurring most frequently in the frontal lobe. MGMT methylated tumors with the IDH1 mutation tended to occur in the left frontal lobe. EGFR amplified and EGFR variant 3-expressing tumors occurred most frequently in the left temporal lobe. A similar region in the left temporal lobe was associated with favorable response to radiochemotherapy and increased survival.
CONCLUSIONS: Radiographic atlases for specific phenotypes provide insight into overlap between prognostic variables and may help to identify niche locations for cancer cells of origin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22997168      PMCID: PMC7964888          DOI: 10.3174/ajnr.A3253

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Whitney B Pope; Taryar M Zaw; Heidi Phillips; Shadi Lalezari; Phioanh L Nghiemphu; Hassana Ibrahim; Kourosh M Naeini; Robert J Harris; Albert Lai
Journal:  Neuroimage       Date:  2011-10-07       Impact factor: 6.556

2.  Asymmetry of the lateral (sylvian) fissures in man.

Authors:  A B Rubens; M W Mahowald; J T Hutton
Journal:  Neurology       Date:  1976-07       Impact factor: 9.910

3.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Authors:  Albert Lai; Anh Tran; Phioanh L Nghiemphu; Whitney B Pope; Orestes E Solis; Michael Selch; Emese Filka; William H Yong; Paul S Mischel; Linda M Liau; Surasak Phuphanich; Keith Black; Scott Peak; Richard M Green; Cynthia E Spier; Tatjana Kolevska; Jonathan Polikoff; Louis Fehrenbacher; Robert Elashoff; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

4.  Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Authors:  J A Carrillo; A Lai; P L Nghiemphu; H J Kim; H S Phillips; S Kharbanda; P Moftakhar; S Lalaezari; W Yong; B M Ellingson; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-09       Impact factor: 3.825

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas.

Authors:  Qijin Xu; Xiangpeng Yuan; Gentao Liu; Keith L Black; John S Yu
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

7.  Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.

Authors:  E W Newcomb; H Cohen; S R Lee; S K Bhalla; J Bloom; R L Hayes; D C Miller
Journal:  Brain Pathol       Date:  1998-10       Impact factor: 6.508

8.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis.

Authors:  Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

9.  Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.

Authors:  Pascal O Zinn; Bhanu Mahajan; Bhanu Majadan; Pratheesh Sathyan; Sanjay K Singh; Sadhan Majumder; Ferenc A Jolesz; Rivka R Colen
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

Review 10.  Stem cells of ependymoma.

Authors:  H Poppleton; R J Gilbertson
Journal:  Br J Cancer       Date:  2006-12-19       Impact factor: 7.640

View more
  84 in total

1.  Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.

Authors:  Benjamin M Ellingson; Albert Lai; Huytram N Nguyen; Phioanh L Nghiemphu; Whitney B Pope; Timothy F Cloughesy
Journal:  Clin Cancer Res       Date:  2015-04-21       Impact factor: 12.531

2.  Can lateral ventricle contact predict the ontogeny and prognosis of glioblastoma?

Authors:  Sheng Han; Xiang Li; Bo Qiu; Tao Jiang; Anhua Wu
Journal:  J Neurooncol       Date:  2015-05-26       Impact factor: 4.130

3.  Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma.

Authors:  Damir Nizamutdinov; Eileen M Stock; Jad A Dandashi; Eliana A Vasquez; Ying Mao; Samantha Dayawansa; Jun Zhang; Erxi Wu; Ekokobe Fonkem; Jason H Huang
Journal:  World Neurosurg       Date:  2017-09-23       Impact factor: 2.104

Review 4.  Brain stem cells as the cell of origin in glioma.

Authors:  Aram S Modrek; N Sumru Bayin; Dimitris G Placantonakis
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

Review 5.  Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics.

Authors:  Benjamin M Ellingson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

6.  The subventricular zone concept: ready for therapeutic implications?

Authors:  Gabriel C T Garcia; Frederic G Dhermain
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

7.  Neural stem cells promote glioblastoma formation in nude mice.

Authors:  J Wang; J Liu; H Meng; Y Guan; Y Yin; Z Zhao; G Sun; A Wu; L Chen; X Yu
Journal:  Clin Transl Oncol       Date:  2019-04-03       Impact factor: 3.405

8.  "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.

Authors:  Rajan Jain; Derek R Johnson; Sohil H Patel; Mauricio Castillo; Marion Smits; Martin J van den Bent; Andrew S Chi; Daniel P Cahill
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

9.  Does risk of brain cancer increase with intracranial volume? A population-based case control study.

Authors:  Even Hovig Fyllingen; Tor Ivar Hansen; Asgeir Store Jakola; Asta Kristine Håberg; Øyvind Salvesen; Ole Solheim
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

10.  Tumor location and patient age predict biological signatures of high-grade gliomas.

Authors:  Roberto Altieri; Francesco Zenga; Alessandro Ducati; Antonio Melcarne; Fabio Cofano; Marco Mammi; Giuseppe Di Perna; Riccardo Savastano; Diego Garbossa
Journal:  Neurosurg Rev       Date:  2017-08-31       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.